| ID | 10319 |
| Vaccine Name | Recombinant SARS-CoV-2 vaccine (Sf9 Cell) |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Phase 3 |
| Manufacturer | West China Hospital, Sichuan University |
| Year of Manufacturing | 2021 |
| Manufacturing Country | China |
| Age | 18 years and above |
| Dosage | 3 doses on day 0, 21 and 42 |
| Administration Route | Intramuscular |
| Adjuvant | Aluminum (aluminium hydroxide) |
| Target Strain | SARS-CoV-2 receptor-binding domain from spike protein |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT04887207 |
| Reference Link | https://clinicaltrials.gov/show/NCT04887207 |
| Additional Links | https://clinicaltrials.gov/ct2/show/NCT04530656
|